Bharat Biotech pursues Covid-19 vaccine approval in over 40 nations – ET HealthWorld
India’s Bharat Biotech is within the means of submitting regulatory paperwork for approval of its Covid-19 vaccine, COVAXIN, in additional than 40 nations, the corporate instructed Reuters late on Wednesday.
“We have submitted our documentation in Brazil and other countries and await their approval. We plan to export several million doses to Brazil,” the corporate mentioned in an emailed assertion. “Pricing of COVAXIN for international markets will be based upon supply timelines, purchase commitments and procurement volumes,” it added.
Bharat Biotech, which final Tuesday had instructed Reuters it could export doses of COVAXIN to Brazil and the United Arab Emirates by the tip of the week, didn’t identify different nations and didn’t give precise figures on doses it expects to export.
The corporate has additionally entered into an settlement with U.S. drug developer Ocugen Inc for the commercialization of COVAXIN in the US, which has seen essentially the most variety of infections on the earth.
COVAXIN is likely one of the two vaccines accredited for emergency use in India, although efficacy knowledge from its late-stage trial is but to be printed.
Bharat Biotech expects outcomes from an ongoing trial involving 25,800 members in India solely by March, although the nation’s drug regulator has referred to as the vaccine secure and efficient amid criticism from some docs and well being consultants.
COVAXIN is at present being utilized by India in its vaccination marketing campaign, which has already coated greater than 9 million well being staff, and goals to cowl 300 million folks by August. Bharat Biotech has provided 5.5 million doses to the federal government and can promote an extra 4.5 million doses.
India, with almost 11 million coronavirus instances, has the second highest variety of infections on the earth, although some consultants imagine the worst of the illness has handed within the nation.